Sökresultat - Eric Laille

  • Visas 1 - 9 av 9 resultat
Förfina resultatet
  1. 1
    Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies

    Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies av Eric Laille, Tao Shi, Guillermo Garcia‐Manero, Christopher R. Cogle, Steven D. Gore, Joel Hetzer, Keshava Kumar, Barry Skikne, Kyle J. MacBeth

    Publicerad 2015
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  2. 2
    CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes

    CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes av Marcos de Lima, Betül Oran, Richard E. Champlin, Esperanza B. Papadopoulos, Sergio Giralt, Bart L. Scott, Basem M. William, Joel Hetzer, Eric Laille, Becky Hubbell, Barry Skikne, Charles Craddock

    Publicerad 2018
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  3. 3
    Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia

    Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia av Guillermo Garcia‐Manero, Steven D. Gore, Christopher R. Cogle, Renee Ward, Tao Shi, Kyle J. MacBeth, Eric Laille, Heidi Giordano, Sarah Sakoian, Elias Jabbour, Hagop M. Kantarjian, Barry Skikne

    Publicerad 2011
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  4. 4
    Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies

    Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies av Michael R. Savona, Kathryn S. Kolibaba, Paul Conkling, Edwin C. Kingsley, Carlos Becerra, John C. Morris, Robert M. Rifkin, Eric Laille, A. J. Kellerman, Stacey M. Ukrainskyj, Qian Dong, Barry Skikne

    Publicerad 2018
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  5. 5
    Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

    Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes av Guillermo Garcia‐Manero, Steven D. Gore, Suman Kambhampati, Bart L. Scott, Ayalew Tefferi, Christopher R. Cogle, William J. Edenfield, Joel Hetzer, Kailash Kumar, Eric Laille, Tao Shi, Kyle J. MacBeth, B. Skikne

    Publicerad 2015
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  6. 6
    Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors

    Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors av Lillian L. Siu, Роберто Пили, Ignacio Durán, Wells A. Messersmith, Eric X. Chen, Rana Sullivan, Martha MacLean, Serina King, Shirley Brown, Gregory K. Reid, Zuomei Li, Ann Kalita, Eric Laille, Jeffrey M. Besterman, Robert E. Martell, Michael A. Carducci

    Publicerad 2008
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  7. 7
    Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

    Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia av Guillermo Garcia‐Manero, Sarit Assouline, Jorge E. Cortés, Zeev Estrov, Hagop M. Kantarjian, Hui Yang, Willie Newsome, Wilson H. Miller, Caroline Rousseau, Ann Kalita, Claire Bonfils, Marja Dubay, T. Patterson, Zuomei Li, Jeffrey M. Besterman, Gregory K. Reid, Eric Laille, Robert E. Martell, Mark D. Minden

    Publicerad 2008
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  8. 8
    Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes

    Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes av Guillermo Garcia‐Manero, Valeria Santini, António Almeida, Uwe Platzbecker, Anna Jonášová, Lewis R. Silverman, José Falantes, Gianluigi Reda, Francesco Buccisano, Pierre Fenaux, Rena Buckstein, María Díez‐Campelo, Stephen Larsen, David Valcárcel, Paresh Vyas, Valentina Giai, Esther Natalie Olíva, Jake Shortt, Dietger Niederwieser, Moshe Mittelman, Luana Fianchi, Ignazia La Torre, Judy Zhong, Eric Laille, Daniel L. Menezes, Barry Skikne, C.L. Beach, Aristoteles Giagounidis

    Publicerad 2021
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  9. 9
    Enasidenib vs conventional care in older patients with late-stage mutant-<i>IDH2</i> relapsed/refractory AML: a randomized phase 3 trial

    Enasidenib vs conventional care in older patients with late-stage mutant-<i>IDH2</i> relapsed/refractory AML: a randomized phase 3 trial av Stéphane de Botton, Pau Montesinos, Andre C. Schuh, Cristina Papayannidis, Paresh Vyas, Andrew H. Wei, Hans Beier Ommen, С. В. Семочкин, Hee‐Je Kim, Richard A. Larson, Jaime Koprivnikar, Olga Frankfurt, Felicitas Thol, Jörg Chromik, Jenny Byrne, Arnaud Pigneux, Xavier Thomas, Olga Salamero, María‐Belén Vidriales, Vadim Doronin, Hartmut Döhner, Amir T. Fathi, Eric Laille, Xin Yu, Maroof Hasan, Patricia Martín-Regueira, Courtney D. DiNardo

    Publicerad 2022
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:

Sökverktyg: